A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
← catalyst calendarNCT07629726 · readout ≤ 254 d
Sponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
72estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hematologic Neoplasms
Intervention
- Drug: KK2430
Primary outcomes
what the primary-completion date above is the date OFDose Level Toxicity (DLT)
measured Endpoint 28 days after first dose
Adverse Events (AEs)
measured Signing of ICF through study completion for an average of 1.5 years
Pregnancy Test
measured Screening through study completion, an average of 1.5 years
ECG QT Interval
measured Treatment period, an average of 3months
ECG QRS Interval
measured Treatment period, an average of 3months
Vital Sign Measurements
measured Treatment period, an average of 3 months
Vital Sign Measurements
measured Treatment period, an average of 3 months
Vital Sign Measurements
measured Treatment period, an average of 3 months
Vital Sign Measurements
measured Treatment period, an average of 3 months
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed